- Trials with a EudraCT protocol (176)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
176 result(s) found for: Sodium MRI.
Displaying page 2 of 9.
EudraCT Number: 2011-003475-11 | Sponsor Protocol Number: UCL/11/0083 | Start Date*: 2011-11-15 | |||||||||||
Sponsor Name:University College London (UCL) | |||||||||||||
Full Title: A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis | |||||||||||||
Medical condition: Acute demyelinating optic neuritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004740-36 | Sponsor Protocol Number: MINT (CRO1834) | Start Date*: 2011-08-04 | |||||||||||
Sponsor Name:Imperial College, London | |||||||||||||
Full Title: Melatonin As A Novel Neuroprotectant In Preterm Infants−Trial Study | |||||||||||||
Medical condition: Brain injury from prematurity | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003260-32 | Sponsor Protocol Number: 13090 | Start Date*: 2013-12-04 |
Sponsor Name: | ||
Full Title: The Effects of Isovolumetric and Isoeffective Infusions of Colloid Versus Crystalloid on Renal Blood Flow and Cardiac Output | ||
Medical condition: Anaesthesia | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004596-31 | Sponsor Protocol Number: NL62772 | Start Date*: 2019-03-25 | ||||||||||||||||
Sponsor Name:UMC Utrecht | ||||||||||||||||||
Full Title: CeRebrUm and CardIac protection with Allopurinol in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass | ||||||||||||||||||
Medical condition: Brain injury in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001948-21 | Sponsor Protocol Number: 2019-28 | Start Date*: 2019-09-03 |
Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE | ||
Full Title: Double-blind randomised placebo controlled study evaluating local co-administration of autologous ADIpose derived stromal vascular fraction with microfat for refractory perianal CROHN’s fistulas. | ||
Medical condition: Crohn’s disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004999-19 | Sponsor Protocol Number: 191001 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Department of infectious diseases, Hvidovre Hospital | |||||||||||||
Full Title: Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppress... | |||||||||||||
Medical condition: Human immunodeficiency viruses (HIV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000221-20 | Sponsor Protocol Number: Nano-Cl_iv | Start Date*: 2014-10-23 |
Sponsor Name:University Hospital Zürich | ||
Full Title: Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial | ||
Medical condition: Clinically Isolated Syndrome and Relapsing-remitting Multiple Sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002076-41 | Sponsor Protocol Number: 0667 | Start Date*: 2018-08-23 | ||||||||||||||||
Sponsor Name:University of Leicester | ||||||||||||||||||
Full Title: A RANDOMISED CONTROLLED TRIAL OF PRE-SURGERY SODIUM VALPROATE, FOR THE PREVENTION OF ORGAN INJURY IN CARDIAC SURGERY: Val-CARD | ||||||||||||||||||
Medical condition: Reduction of myocardial and kidney injury risk of post cardiac surgery by increasing the expression of genes that promote myocardial mitochondrial homeostasis via effects on chromatin histone deace... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000111-26 | Sponsor Protocol Number: MEIN/10/Ran-Did/002 | Start Date*: 2011-07-01 | |||||||||||
Sponsor Name:A. MENARINI PHARMA U.K., | |||||||||||||
Full Title: Effect of late sodium current inhibition on MRI measured diastolic dysfunction and myocardial perfusion reserve in aortic stenosis - a proof of concept study. | |||||||||||||
Medical condition: Aortic stenosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000394-21 | Sponsor Protocol Number: A6301094 | Start Date*: 2016-07-20 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN® (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES. | |||||||||||||
Medical condition: Acute treatment and secondary prophylaxis of recurrent VTE (venous thromboembolism) in children with or without cancer. | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SI (Completed) PL (Completed) GB (Completed) DE (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001735-49 | Sponsor Protocol Number: CTU/2015/174 | Start Date*: 2019-07-01 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase II/III, non-inferiority trial | |||||||||||||
Medical condition: Patients with stroke or other ischaemic brain injury who have antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000566-12 | Sponsor Protocol Number: SA-NXY-0012 | Start Date*: 2005-01-25 |
Sponsor Name:AstraZeneca AB | ||
Full Title: CHANT (Cerebral Hemorrhage And NXY Treatment) A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase IIb study to assess the safety and tolerability of 72 hours intraven... | ||
Medical condition: Acute intracerebral hemorrhage not caused by trauma or tumor or being secondary to acute ischemic stroke, i.e hemorrhagic transformation. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004823-21 | Sponsor Protocol Number: PBI-4050-CT-9-10 | Start Date*: 2017-10-25 | |||||||||||
Sponsor Name:Prometic Biosciences Inc. | |||||||||||||
Full Title: An Open-Label Rollover Study of PBI-4050 in Subjects with Alström Syndrome | |||||||||||||
Medical condition: Alström Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003288-24 | Sponsor Protocol Number: GRN163LMYF3001 | Start Date*: 2021-05-10 | |||||||||||
Sponsor Name:Geron Corporation | |||||||||||||
Full Title: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/... | |||||||||||||
Medical condition: Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003226-19 | Sponsor Protocol Number: MS-LAQ-301 | Start Date*: 2007-09-05 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd | |||||||||||||
Full Title: Study Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laq... | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) HU (Completed) GB (Completed) FR (Completed) CZ (Completed) LV (Completed) AT (Completed) LT (Completed) ES (Completed) EE (Completed) PT (Prematurely Ended) SE (Completed) IT (Completed) BG (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005744-34 | Sponsor Protocol Number: iCHF-2 | Start Date*: 2019-01-03 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Centre Hamburg-Eppendorf | ||||||||||||||||||||||||||||
Full Title: Randomized, Double-Blinded, Controlled Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency | ||||||||||||||||||||||||||||
Medical condition: Patients With Cardiovascular Disease and Concomitant Iron Deficiency Cohort A: Acute myocardial infarction (AMI) Cohort B: Paroxysmal atrial fibrillation or persitent atrial fibrillation (AF) Coho... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000352-36 | Sponsor Protocol Number: HP-ALS-TIA | Start Date*: 2020-04-27 | |||||||||||
Sponsor Name:Christoffer Laustsen | |||||||||||||
Full Title: MRI of neurometabolic impairment in ALS and TIA using hyperpolarized pyruvate | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis Transient ischemic attack | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001755-41 | Sponsor Protocol Number: GV971-007 | Start Date*: 2021-02-10 | |||||||||||
Sponsor Name:Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | |||||||||||||
Full Title: A Phase 3, multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy and safety of sodium oligomannate (GV-971) in treatment of mild to mode... | |||||||||||||
Medical condition: mild to moderate Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002798-21 | Sponsor Protocol Number: 13337 | Start Date*: 2018-06-19 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A multi-centre, blinded, randomised, placebo-controlled trial assessing the clinical and cost effectiveness of a 12 month course of oral alendronate (70mg weekly) in patients presenting with avascu... | |||||||||||||
Medical condition: Early stage (Ficat 1 or 2), symptomatic, Avascular Necrosis (AVN) of the femoral head | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000864-28 | Sponsor Protocol Number: DAP-PEDOST-11-03 | Start Date*: 2014-01-02 | |||||||||||||||||||||
Sponsor Name:Cubist Pharmaceuticals, LLC | |||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogeno... | |||||||||||||||||||||||
Medical condition: Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) IT (Completed) ES (Completed) GR (Completed) LV (Completed) GB (Completed) EE (Completed) BG (Completed) FR (Completed) SI (Completed) Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
